ClinicalTrials.gg
TerminatedNCT00767494Updated Sep 19, 2012

Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

A Phase 3 interventional study of Travoprost/Brinzolamide fixed combination and Azopt in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Terminated at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-19.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Why this study was terminated
Project Cancelled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 93 studies in Glaucoma by Alcon — none open to participants now, none under way, none of them phase 3. Glaucoma · Alcon.

Enrollment
74th of 77
17 · median 112
Started
2008
with 6 others
Phase 3
26 of 93
none open now
Registered
42nd of 93
by date

Among the 93 studies in Glaucoma by Alcon, this one is the 74th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2008, is one of 26 in phase 3, and was the 42nd registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 93 studies in Glaucoma by Alcon is open now. The open studies under Glaucoma, anywhere →

Who these studies take

Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 93 studies in Glaucoma by Alcon as a file.
02

Study summary

The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs. AZOPT dosed BID in patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension

Keywords

  • OAG
  • OH
  • Open-angle glaucoma or ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 YOA or older
  • Either gender or any race
  • OAG or OHT
  • Currently on stable (at least 4 weeks) IOP lowering medication
  • IOP at screening visit ≥ 18mmHg in at least one eye
  • Mean IOP in same eye (at both eligibility 1\&2 visits
  • 24 and 36 mmHg at 9AM
  • 21 and 36 mmHg at 11AM and 4PM
  • Able to discontinue use of IOP lowering medication for a minimum wash out period of 5 to 28 days prior to eligibility visit 1

Exclusion criteria

Exclusion Criteria:

Related to disease condition being investigated (OAG or OHT) in either eye

  • Severe central visual field loss
  • Angle shaffer grade \< 2
  • C/D ratio >0.8(horizontal or vertical measurement)

Related to ocular patient history or current ocular condition in either eye

  • BSCVA worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal)
  • Ocular infection or inflammation or laser surgery within the last 3 months
  • Intraocular surgery or trauma with the last 6 months
  • Any abnormality preventing reliable applanation tonometry
  • History or chronic, recurrently or current severe inflammatory disease
  • History of or current or progressive retinal disease
  • History of or current ocular pathology(including severe dry eye) that would affect the conduct of the study

Related to systemic or ocular medication in either eye

  • Allergy/ to study medications
  • Unable to discontinue at least 4 weeks prior to the study or unable to remain off these medications during the study period
  • Use of oral CAIs during the study
  • Recent use (\<4 weeks prior to the study) of Aspirin (>1 gram)
  • Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP
  • Therapy with another agent within 30 days prior to the Screening Visit
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    1

    Travoprost/Brinzolamide AM, Vehicle PM

    Drug: Travoprost/Brinzolamide fixed combination

  • Experimental
    2

    Travoprost/Brinzolamide PM, Vehicle AM

    Drug: Travoprost/Brinzolamide fixed combination

  • Active comparator
    3

    AZOPT AM and PM

    Drug: Azopt

  • Active comparator
    4

    TRAVATAN PM, Vehicle AM

    Drug: Travatan

Interventions

  • DrugTravoprost/Brinzolamide fixed combination

    Eye Drops, suspension once daily

  • DrugAzopt

    Eye Drop Suspension, 1 drop BID

  • Eye Drop Solution, 1 drop BID

06

What researchers measure

Primary outcomes

  1. Mean IOP

    Time frame: 9, 11, and 16:00 time points at Week 12

Secondary outcomes

  1. Mean diurnal IOP at Week 12

    Time frame: results pooled across 9,11, and 16:00 time points

07

Study locations

1 site
  • Brussels, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2008
First posted
Oct 7, 2008
Start
Oct 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Last update
Sep 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00767494
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Oct 7, 2008
Start date
Oct 2008
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Sep 19, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion